Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
May 08 2020 - 3:03PM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
the closing of its previously announced underwritten public
offering of 10,465,000 shares of its common stock, including the
exercise in full by the underwriters of their option to purchase an
additional 1,365,000 shares, at a public offering price of $13.75
per share. The gross proceeds to Kura from the offering, before
underwriting discounts and commissions and other offering expenses
payable by Kura, were approximately $143.9 million.
SVB Leerink, Cowen and Credit Suisse acted as
joint bookrunning managers in the offering. JMP Securities and H.C.
Wainwright & Co. acted as co-managers in the offering.
The securities described above were offered by
Kura pursuant to a shelf registration statement on Form S-3,
including a base prospectus, that was previously filed by Kura with
the Securities and Exchange Commission (the “SEC”) and that was
declared effective on August 28, 2019. A final
prospectus supplement and accompanying prospectus relating to the
offering have been filed with the SEC and are available for free on
the SEC’s website located at http://www.sec.gov. Copies of
the final prospectus supplement and the accompanying prospectus
relating to the offering may be obtained from: SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at (800) 808-7525, ext. 6218, or by
email at syndicate@svbleerink.com; Cowen and Company, LLC c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by email at PostSaleManualRequests@broadridge.com, or
by phone at (833) 297-2926; or Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, Eleven Madison
Avenue, 3rd Floor, New York, NY 10010, or by telephone at
(800) 221-1037, or by email
at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Kura Oncology
Kura Oncology is a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer. Kura’s pipeline
consists of two wholly-owned small molecule drug candidates that
target cancer signaling pathways where there is a strong scientific
and clinical rationale to improve outcomes by identifying those
patients most likely to benefit from treatment. Kura’s most
advanced drug candidate is tipifarnib, a potent, selective and
orally bioavailable farnesyl transferase inhibitor currently in a
registration-directed trial in patients with recurrent or
metastatic HRAS mutant head and neck squamous cell carcinoma
(HNSCC). Kura’s pipeline is also highlighted by KO-539, a
potentially first-in-class, potent and selective inhibitor of the
menin-MLL protein-protein interaction currently in a Phase 1/2A
clinical trial in patients with relapsed/refractory AML.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke ICR(858)
356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024